Overall, from current levels, the risk-reward for both stocks looks fairly balanced, especially as the GLP-1 market becomes more competitive
Heise T, Mari A, DeVries JH et al (2022) Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
These typically occur in 20-40% of patients and include: Nausea (most common, especially during dose increases) Vomiting Diarrhea Stomach pain Decreased appetite Constipation These side effects usually improve over time as your body adjusts to the medication
doi: 10.1056/NEJMc2504728 45
Customer Support & Reviews Noom provides in-app coaching and messaging with your care team